SCHEMBL13043247

SCHEMBL13043247

Cc1ccc(-c2nc3nc(N)nc(N)c3nc2-c2ccc(O)c(O)c2)cc1O

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 13/20 0.84
MTOR P42345 3/20 0.58
PIK3CD O00329 2/20 0.58
ABL1 P00519 2/20 0.58
EGFR P00533 2/20 0.58
PIK3CA P42336 2/20 0.58
PIK3CB P42338 2/20 0.58
PI4KB Q9UBF8 2/20 0.58
PIK3C2B O00750 1/20 0.58
PDXK O00764 1/20 0.58
GAK O14976 1/20 0.58
MAP3K7 O43318 1/20 0.58
RIPK2 O43353 1/20 0.58
PIP5K1C O60331 1/20 0.58
STK16 O75716 1/20 0.58
PIK3C2G O75747 1/20 0.58
PRKD3 O94806 1/20 0.58
OXSR1 O95747 1/20 0.58
LATS1 O95835 1/20 0.58
ERBB2 P04626 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3734924 0.92 PIK3CG (1.00) PIK3CGMTORPIK3CDABL1EGFR
Hydrochloric Acid SCHEMBL3731655 0.90 PIK3CG (0.97) PIK3CGMTORPIK3CDABL1EGFR
Hydrochloric Acid SCHEMBL3536075 0.90 PIK3CG (0.97) PIK3CGMTORPIK3CDABL1EGFR
SCHEMBL14325117 0.84 PIK3CG (0.78) PIK3CGMTORPIK3CDABL1EGFR
SCHEMBL13043249 0.83 PIK3CG (0.85) PIK3CGMTORPIK3CDABL1EGFR
SCHEMBL3533560 0.73 PIK3CG (1.00) PIK3CGMTORPIK3CDABL1EGFR
Tg100-115 SCHEMBL31238338 0.73 PIK3CG (1.00) PIK3CGMTORPIK3CDABL1EGFR
Tg100-115 SCHEMBL29506727 0.73 PIK3CG (1.00) PIK3CGMTORPIK3CDABL1EGFR
Tg100-115 SCHEMBL360279 0.73 PIK3CG (1.00) PIK3CGMTORPIK3CDABL1EGFR
Tg100-115 SCHEMBL29369340 0.73 PIK3CG (1.00) PIK3CGMTORPIK3CDABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100278811-A1 VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF TARGEGEN INC. 2010-11-04 US disclosed
US-20070208019-A1 Vasculostatic agents and methods of use thereof TARGEGEN, INC. 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208019-A1 Vasculostatic agents and methods of use thereof RBP1, RBP4, VCAM1 PIK3CG 2378/4885MTOR 2214/4885PIK3CD 3513/4885
US-20100278811-A1 VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF RBP1, RBP4, VCAM1 PIK3CG 2378/4885MTOR 2214/4885PIK3CD 3513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.